Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.
LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) began 2025 with a pair of potentially ...
6h
MarketBeat on MSNBiogen Stock Is Mutating Into a Value PlayBiogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...
The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outweigh ...
Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results